Bristol-Myers Squibb Company (BMY)
Bristol Myers (BMY) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol Myers Squibb Logs Higher Sales, Profit
Bristol Myers Squibb posted higher first-quarter revenue boosted by its portfolio of newer treatments for heart and blood conditions.
Exploring Analyst Estimates for Bristol Myers (BMY) Q1 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Bristol Myers (BMY) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Bristol-Myers Squibb: 'Strong Buy' As 2026 Milestones Could Bolster Its Prospects
Bristol-Myers Squibb retains a "Strong Buy" rating, driven by robust Growth Portfolio expansion and strategic pipeline execution. The company's growth portfolio now nears 60% of total revenues, growing 16% YoY, effectively offsetting impending patent cliff losses. Key pipeline assets iberdomide and mezigdomide target relapsed/refractory multiple myeloma, with iberdomide's FDA decision expected by August 2026.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
BMY heads into Q1 earnings with strong growth portfolio momentum, but legacy drug declines and generic pressure may weigh on overall revenue performance.
Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade)
Bristol-Myers Squibb remains a solid, undervalued investment but is no longer a compelling 'Buy' due to muted growth prospects. BMY's growth portfolio now surpasses its legacy portfolio, yet overall revenue is expected to decline as analysts remain pessimistic about pipeline execution. Dividend yield stands at 4.3% and is well-covered by free cash flow, while debt levels, though reduced, require monitoring if revenue declines persist.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
61,789 Shares in Bristol Myers Squibb Company $BMY Bought by CPC Advisors LLC
CPC Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 61,789 shares of the biopharmaceutical company's stock, valued at approximately $3,333,000. A number of other hedge funds
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
BMY stands out vs GILD, supported by a cheaper valuation, strong growth portfolio, and improving earnings outlook despite generic headwinds.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1?
BMY pivots to growth portfolio as legacy drugs decline, with rising new therapies helping offset revenue erosion and reshape the long-term outlook.
Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff
Bristol-Myers Squibb is deeply undervalued at 8.9x forward earnings due to overblown patent cliff fears on Eliquis and Opdivo. The Growth Portfolio now generates 55% of revenue, grew 17% in FY2025, and is guided to continue double-digit growth into 2026. Key catalysts include the August 2026 FDA decision on iberdomide and the upcoming milvexian Phase 3 results, both with multi-billion dollar potential.
